<unk>  has undergone clinical trials for the treatment of various cancers, including pancreatic and prostate cancers, V617F JAK2 positive polycythemia vera and essential thrombocytosis, and refractory neuroblastoma. The most significant effort was invested in developing<unk>  for the treatment of acute myelogenous leukemia (AML). 24% of the adult AML-affected population exhibits FLT3 mutations, which are associated with an increased likelihood of relapse and mortality after treatment above the general AML population. FLT3 mutations suppress apoptosis in mutated cells, but<unk>  has the potential to overcome this suppression by inhibiting FLT3 kinase activity.
Lestaurtinib
Mobocertinib
Osimertinib
Selpercatinib
Upadacitinib
Brigatinib
Baricitinib
Axitinib